Marval Biosciences (San Diego, CA) a preclinical-stage biopharma company focused on the reformulation of contrast dyes for CT scans using liposomal nanoparticles, closed a $2.5M Series B financing. Participants include DFJ Frontier and DFJ Mercury.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.